15 research outputs found

    Mammographic density and breast cancer risk: current understanding and future prospects

    Get PDF
    Variations in percent mammographic density (PMD) reflect variations in the amounts of collagen and number of epithelial and non-epithelial cells in the breast. Extensive PMD is associated with a markedly increased risk of invasive breast cancer. The PMD phenotype is important in the context of breast cancer prevention because extensive PMD is common in the population, is strongly associated with risk of the disease, and, unlike most breast cancer risk factors, can be changed. Work now in progress makes it likely that measurement of PMD will be improved in the near future and that understanding of the genetics and biological basis of the association of PMD with breast cancer risk will also improve. Future prospects for the application of PMD include mammographic screening, risk prediction in individuals, breast cancer prevention research, and clinical decision making

    Pathogen reduction/inactivation of products for the treatment of bleeding disorders:what are the processes and what should we say to patients?

    Get PDF
    Patients with blood disorders (including leukaemia, platelet function disorders and coagulation factor deficiencies) or acute bleeding receive blood-derived products, such as red blood cells, platelet concentrates and plasma-derived products. Although the risk of pathogen contamination of blood products has fallen considerably over the past three decades, contamination is still a topic of concern. In order to counsel patients and obtain informed consent before transfusion, physicians are required to keep up to date with current knowledge on residual risk of pathogen transmission and methods of pathogen removal/inactivation. Here, we describe pathogens relevant to transfusion of blood products and discuss contemporary pathogen removal/inactivation procedures, as well as the potential risks associated with these products: the risk of contamination by infectious agents varies according to blood product/region, and there is a fine line between adequate inactivation and functional impairment of the product. The cost implications of implementing pathogen inactivation technology are also considered

    A novel continuous microfluidic reactor design for the controlled production of high-quality semiconductor nanocrystals

    No full text
    An innovative microfluidic reactor concept for the production of high quality semiconductor nanocrystals is presented. The reactor features a droplet-based, two phase flow design that eliminates the dispersion-induced broadening of the particle size distribution that is characteristic of other microfluidic designs. The flow channels in the design are arranged to spiral in and out of novel reaction coin structures that are designed to allow the thermal profile of the reactor to be tailored to the requirements of specific nanocrystal synthesis operations. A simplified prototype reactor has been constructed and tested to demonstrate the feasibility of the reactor concept. Broader impacts of the design concept with respect to the ability to permit unprecedented control over the size distribution of the particles are discussed
    corecore